ALX 0761

Drug Profile

ALX 0761

Alternative Names: ALX-0761; Anti-IL-17A/F Nanobody; M-1095; MSB-0010841

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ablynx
  • Developer Merck Serono
  • Class Anti-inflammatories; Antipsoriatics; Proteins
  • Mechanism of Action IL17A protein inhibitors; IL17F protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Psoriasis
  • No development reported Inflammation

Most Recent Events

  • 30 Mar 2017 Avillion and Merck Serono enter a clinical co-development agreement to develop ALX 0761
  • 30 Mar 2017 Avillion plans a phase II trial for Plaque psoriasis
  • 06 Mar 2017 Interim efficacy and adverse events data from a phase Ia trial in Psoriasis presented at the 75th Annual Meeting of the American Academy of Dermatology (AAD-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top